Sangamo Jumps on Newest Pfizer Collaboration

Health and Healthcare

Published: January 3, 2018 10:45 am

Last Updated: January 12, 2020 4:54 am

Sangamo Therapeutics Inc. (NASDAQ: SGMO) shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer Inc. (NYSE: PFE) for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).

Under the terms of the collaboration agreement, Sangamo will receive a $12 million upfront payment from Pfizer. Sangamo will be responsible for the development of ZFP-TF candidates. Pfizer will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization

Also, Sangamo is eligible to receive potential development and commercial milestone payments of up to $150 million, as well as tiered royalties on net sales.

Keep in mind that Sangamo has a market cap of only roughly $1.5 billion.

Back in May 2017, Sangamo and Pfizer entered into an exclusive, global collaboration and license agreement for the development and commercialization of potential gene therapy products for hemophilia A, including SB-525, which entered the clinic in August 2017.

Dr. Sandy Macrae, CEO of Sangamo, commented:

We are excited to continue our collaborative relationship with Pfizer with this new program using Sangamo’s zinc finger protein technology to develop a potential gene therapy for patients with certain forms of ALS and FTLD, devastating diseases with very limited treatment options. The precision and flexibility of zinc finger proteins enables targeting of virtually any genetic mutation. Collaboration with the right partner for a given therapeutic application is a key component of our corporate strategy and enables us to pursue the vast opportunity set of our platform.

Shares of Sangamo were last seen up about 6% at $18.60, with a consensus analyst price target of $17.33 and a 52-week range of $3.00 to $18.70.

Pfizer was trading at $36.44 a share, in a 52-week range of $30.90 to $37.35 and a consensus price target of $38.29.

The Average American Has No Idea How Much Money You Can Make Today ^(Sponsor)

The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.

But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

¹https://www.fdic.gov/national-rates-and-rate-caps